11 बजे - अनुवाद करना

Leukemia Vaccine Succeeds in Pivotal Phase 3 Trial

A first of its kind vaccine for acute myeloid leukemia succeeded in a Phase 3 clinical trial. The vaccine is called galinpepimut-S and was developed by Sellas Life Sciences with Memorial Sloan Kettering Cancer Center. Trial results showed a 41 percent reduction in risk of death for patients who received the vaccine. The treatment trains the immune system to recognize and attack leukemia cells that remain after initial therapy. Researchers said the result marks a major step for a deadly blood cancer with limited options. The vaccine still needs regulatory review and longer follow up to confirm safety and benefit. If approved, doctors could offer a new maintenance option to help patients stay in remission longer.

image
advertisement
"We will never ask you to login, or register through a third-party advertisement."